EyePoint, Inc.
EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on retinal diseases, using its proprietary Durasert E bioerodible implant platform to deliver drugs inside the eye over extended periods. Its lead candidate, DURAVYU, is being developed for wet age-related macular degeneration and diabetic macular edema, while the company also commercializes legacy ophthalmic products and earns collaboration and royalty revenue.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInvestigational retinal disease therapies centered on DURAVYU and EYP-2301.
Legacy marketed eye-disease products including YUTIQ and DEXYCU.
Royalties from partners' net sales under license and collaboration agreements.
Deferred revenue recognition and milestone-related collaboration income.
Products
Reported · share of revenue- License and Collaboration Agreement53.3 %
- Royalty41.6 %
- Products5.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
EyePoint sells to ophthalmologists, retina specialists, and the healthcare systems that use its commercial eye products, while its development-stage programs are aimed at patients with serious retinal diseases such as wet AMD and DME. A meaningful part of revenue also comes indirectly from partners and licensees through royalty and collaboration arrangements rather than direct end-customer sales.
They prescribe or administer EyePoint's eye-disease therapies because the products target chronic retinal conditions requiring repeated treatment.
They buy or license product rights and generate royalty streams tied to their commercial sales.
They purchase commercial ophthalmic products for patient treatment and procedural use.
They are the end beneficiaries of DURAVYU and other retinal therapies, driving physician demand.
Strategy
EyePoint's strategy is to convert its Durasert E delivery platform into a differentiated retinal-disease franchise, with DURAVYU as the lead asset in late-stage trials for two large markets. Near term, the company is balancing clinical execution with cash preservation, while also monetizing legacy products and partner agreements to support funding needs.
Late-stage data is the main value driver and determines regulatory and commercialization prospects.
Clinical-stage development requires ongoing funding before product approval and commercialization.
Longer-duration delivery and multi-mechanism therapy can improve efficacy and dosing convenience versus competitors.
Geography
2025EyePoint is headquartered in Watertown, Massachusetts and operates a commercial manufacturing facility in Northbridge, Massachusetts, so its core operations are concentrated in the United States. The filings also reference international partner relationships, but the excerpts provided do not disclose a country-by-country revenue split.
Share of the revenue the company reports by geography.
Risks
The company faces the usual clinical-stage biotech risks: trial failure, regulatory delay, and the possibility that competitors reach market first with better efficacy or dosing convenience. It also has company-specific exposure to a DOJ investigation tied to sales and marketing practices, dependence on third-party partners and IP licenses, and potential cybersecurity and trade-secret risks that could disrupt operations or damage its competitive position.
- Clinical trial failure or delay for DURAVYUImpact: HighLikelihood: Medium
The lead asset is still investigational, so negative data or slower enrollment would directly reduce pipeline value.
Exposure: wet AMD and DME Phase 3 programs
- DOJ investigation into sales and marketing practicesImpact: HighLikelihood: Medium
A negotiated resolution may require payments, compliance undertakings, or other restrictions that consume cash and management time.
Exposure: DEXYCU-related historical practices
- Dependence on Equinox Science license and vorolanib supplyImpact: HighLikelihood: Medium
Loss of license rights or API access would impair the core DURAVYU program.
Exposure: DURAVYU development
- Competitive pressure in retinal diseaseImpact: MediumLikelihood: Medium
Large incumbents and biosimilars can offer earlier, cheaper, or more established therapies.
Exposure: wet AMD and DME markets
- Cybersecurity and third-party vendor disruptionImpact: MediumLikelihood: Low
Clinical and patient data, as well as outsourced operations, create breach and continuity risk.
Exposure: trial operations and corporate systems
Accounting
Judgemental itemsRoyalty income is tied to partner sales and deferred revenue is recognized as obligations are satisfied, affecting quarter-to-quarter comparability.
Impact: Can create timing swings in reported revenue
Commercial product revenue is recorded net of allowances and reserves, which requires judgment.
Impact: Affects net product sales and gross-to-net deductions
Clinical development costs depend on estimates for CRO and investigator services.
Impact: Can shift R&D expense between periods
Royalty receipts are recognized based on partner reports and later adjusted when actual reports arrive.
Impact: May cause immaterial but recurring revenue adjustments
Similar listed companies
Publicly listed companies with a comparable business focus.
Ocular Therapeutix, Inc
OCUL · Pharmaceutical Preparations
IDEAYA Biosciences, Inc.
IDYA · Pharmaceutical Preparations
IDEAYA Biosciences is a clinical-stage precision oncology company focused on discovering and developing targeted cancer therapies matched to specific molecular alterations.
Kodiak Sciences Inc.
KOD · Biological Products, (No Diagnostic Substances)
Edesa Biotech, Inc.
EDSA · Pharmaceutical Preparations
OKYO Pharma Ltd
OKYO · Biological Products, (No Diagnostic Substances)
OKYO Pharma Ltd is a U.S.-listed clinical-stage biopharmaceutical company focused on developing investigational therapies for neuropathic corneal pain and other anterior segment eye diseases.
ClearPoint Neuro, Inc.
CLPT · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026